Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01
| Autor: | Juan Manuel Mejía-Aranguré, Berenice Sánchez-Jara, José Arellano-Galindo, María Teresa Dueñas-González, Teresa Marín-Palomares, Elva Jiménez-Hernández, María Guadalupe Ortíz-Torres, Xochiketzalli García-Jiménez, Octavio Martínez Villegas, A Ortiz-Fernandez, Héctor Manuel Tiznado-García, Ethel Zulie Jaimes-Reyes, Vilma Carolina Bekker-Méndez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Vincristine Pediatrics medicine.medical_specialty Adolescent Article Subject Population lcsh:Medicine Disease-Free Survival General Biochemistry Genetics and Molecular Biology Risk Factors Prednisone Antineoplastic Combined Chemotherapy Protocols Humans Medicine Child education Mexico education.field_of_study General Immunology and Microbiology business.industry lcsh:R Cytarabine Dana-Farber Cancer Institute Infant Cancer General Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease United States Methotrexate Treatment Outcome Child Preschool Lymphoblastic leukaemia Female Neoplasm Recurrence Local business Research Article medicine.drug |
| Zdroj: | BioMed Research International, Vol 2015 (2015) BioMed Research International |
| ISSN: | 2314-6141 2314-6133 |
| Popis: | Our aim in this paper is to describe the results of treatment of acute lymphoblastic leukaemia (ALL) in Mexican children treated from 2006 to 2010 under the protocol from the Dana-Farber Cancer Institute (DFCI) 00-01. The children were younger than 16 years of age and had a diagnosis of ALL denovo. The patients were classified as standard risk if they were 1–9.9 years old and had a leucocyte count 9/L, precursor B cell immunophenotype, no mediastinal mass, CSF free of blasts, and a good response to prednisone. The rest of the patients were defined as high risk. Of a total of 302 children, 51.7% were at high risk. The global survival rate was 63.9%, and the event-free survival rate was 52.3% after an average follow-up of 3.9 years. The percentages of patients who died were 7% on induction and 14.2% in complete remission; death was associated mainly with infection (21.5%). The relapse rate was 26.2%. The main factor associated with the occurrence of an event was a leucocyte count >100 × 109/L. The poor outcomes were associated with toxic death during induction, complete remission, and relapse. These factors remain the main obstacles to the success of this treatment in our population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|